Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer.
Aged
Antigens, CD
/ analysis
Antineoplastic Agents, Immunological
/ therapeutic use
Female
Humans
Integrin alpha Chains
/ analysis
Male
Memory T Cells
/ drug effects
Middle Aged
Neoplasm Recurrence, Local
/ diagnosis
Nivolumab
/ therapeutic use
Prognosis
Stomach Neoplasms
/ diagnosis
Tertiary Lymphoid Structures
/ diagnosis
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
05
2021
accepted:
23
12
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Nivolumab, an immune checkpoint blocker, has been approved for advanced gastric cancer (GC), but predictive factors of nivolumab's efficacy in patients with GC, especially immune cells such as tissue-resident memory T cells or those forming tertiary lymphoid structures (TLS), remain unclear. Tissue samples were obtained from surgically resected specimens of patients with GC who were treated with nivolumab as third-line or later treatment. Immunohistochemical staining was performed to detect the presence of TLS and CD103+ T cells and assess the association between TLSs and response to nivolumab treatment. A total of 19 patients were analyzed. In patients with partial response (PR) to nivolumab, numerous TLS were observed, and CD103+ T cells were found in and around TLS. Patients with many TLS experienced immune-related adverse events more often than those with few TLS (p = 0.018). The prognosis of patients with TLS high was better than those with TLS low. Patients with a combination of TLS high and CD103 high tended to have a better prognosis than other groups. Our results suggested that TLS status might be a predictor of nivolumab effectiveness.
Identifiants
pubmed: 34995329
doi: 10.1371/journal.pone.0262455
pii: PONE-D-21-14983
pmc: PMC8741034
doi:
Substances chimiques
Antigens, CD
0
Antineoplastic Agents, Immunological
0
Integrin alpha Chains
0
alpha E integrins
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0262455Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Nature. 2019 Jan;565(7739):366-371
pubmed: 30598548
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Nat Immunol. 2018 Jun;19(6):538-546
pubmed: 29777219
Front Immunol. 2015 Feb 23;6:67
pubmed: 25755654
Cancers (Basel). 2014 Apr 23;6(2):969-97
pubmed: 24762633
Cancer Immunol Immunother. 2013 Mar;62(3):405-10
pubmed: 23423351
J Surg Res. 2017 Jul;215:74-82
pubmed: 28688665
BMC Cancer. 2020 Jul 14;20(1):656
pubmed: 32664888
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Sci. 2021 May;112(5):1746-1757
pubmed: 33735485
Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
pubmed: 21779876
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
BMC Cancer. 2019 Oct 21;19(1):974
pubmed: 31638948
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668
pubmed: 28653677
Cancer Immunol Res. 2020 Apr;8(4):479-492
pubmed: 32075801
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Cancer Immunol Immunother. 2020 Aug;69(8):1493-1504
pubmed: 32285170
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045
pubmed: 29599411
Int J Oncol. 2020 Jul;57(1):171-182
pubmed: 32319601
J Immunother Cancer. 2019 Jan 31;7(1):24
pubmed: 30704511
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348